Skip to main content

Table 4 Univariate analysis of several patient, tumor, and treatment parameters.

From: A phase II randomized trial comparing radiotherapy with concurrent weekly cisplatin or weekly paclitaxel in patients with advanced cervical cancer

Factor

p-value

Age

0.29

Number of chemotherapy cycles

0.06

Stage

0.75

Hydronephrosis

0.93

Tumor size

0.16

Delay in Chemotherapy

0.22

Dose to Point A

0.27

HDR brachytherapy

0.84

  1. Only the number of chemotherapy cycles was borderline significant.
Back to article page

Radiation Oncology

ISSN: 1748-717X

Contact us